Skip to content
HowShorted

Stoke Therapeutics, Inc. short interest in 2022

In 2022, Stoke Therapeutics, Inc.'s disclosed short interest ran from 8.42% of shares outstanding on 14 Jan 2022 to 9.73% on 30 Dec 2022, a change of +1.31 percentage points. The year's high was 16.53% on 14 Apr 2022 and its low 8.42% on 14 Jan 2022, averaging 13.07% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 53.08 days on 15 Jul 2022. Full history: Stoke Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Stoke Therapeutics, Inc. in 2022

2022 in figures

Start of year
8.42% (14 Jan 2022)
End of year
9.73% (30 Dec 2022)
Change
+1.31 pp
High
16.53% (14 Apr 2022)
Low
8.42% (14 Jan 2022)
Average
13.07%
Highest days to cover
53.08 (15 Jul 2022)
SEC filings marked
9

Every report in 2022

Stoke Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.42%11.75results (8-K)
31 Jan 20229.89%8.49
15 Feb 20229.91%9.73
28 Feb 202211.59%16.43
15 Mar 202214.33%20.4910-K filed, results (8-K)
31 Mar 202215.54%12.72
14 Apr 202216.53%22.72
29 Apr 202216.52%34.29
13 May 202215.48%16.2510-Q filed, results (8-K)
31 May 202215.78%19.65
15 Jun 202215.85%16.47
30 Jun 202216.15%14.61
15 Jul 202215.64%53.08
29 Jul 202214.52%23.13
15 Aug 202213.29%27.0110-Q filed, results (8-K)
31 Aug 202213.55%31.55
15 Sep 202213.35%18.04
30 Sep 202213.82%24.28
14 Oct 202213.06%19.47
31 Oct 202211.64%16.73
15 Nov 202210.70%9.5410-Q filed, results (8-K)
30 Nov 20229.27%8.33
15 Dec 20229.14%13.32
30 Dec 20229.73%16.26

See also: Stoke Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.